Advanced Therapies and Pharmacogenomics

Cell and Gene Therapy Approval

• While the majority of cell and gene therapies will be appraised by NICE, AWMSG will appraise cell and gene therapies for patients living in Wales if the therapy has been classified as a medicinal product, and has not been submitted for NICE approval. 

Advanced Therapies Wales (ATW)

Midlands and Wales Advanced Therapy Treatment Centre

• The MW-ATTC aims to address the lack of ATMP specific patient and public involvement and engagement (PPIE) activity, leading to a lack of understanding of ATMPs and lower participation in trials. The centre aims to achieve this by:
  
  

  • Raising public awareness of ATMPs – enhancing public & patient understanding through a strategic, collaborative and sustainable approach, ensuring access to accurate, trusted and up to date information.

  • Equity of access to ATMP clinical trials – through the development and implementation of a comprehensive strategy informed by input from stakeholders and guided by finding from reports and studies.

  • Create a Patient Charter for ATMPs – which addresses unmet patient needs, involves key stakeholders and is supported and embedded by the ATMP Engage network.
    
    

• The Centre is based in Velindre University NHS Trust, Cardiff and Vale University Health Board and University Hospitals Birmingham NHS Foundation Trust. It is one of four centres within the UK's Advanced Therapy Treatment Centre network.

NHS Wales Joint Commissioning Committee

• The NHS Wales JCC ATMP Outcomes Programme investigates the clinical and cost effectiveness of ATMPs through the collection and analysis of outcomes data. This data will support decisions on how Wales can sustainably provide ATMPs.
  
  
• The committee’s medical directorate also develop and implement strategies to ensure equitable access to ATMPs in Wales.

Pharmacogenomics in Wales

• A 3-year Pharmacogenomics Delivery Plan for Wales is currently in development by the National Pharmacogenomics Group for Wales (NPGG).
   
• This plan will enable healthcare providers across NHS Wales, in collaboration with key stakeholders, to integrate pharmacogenomic testing into clinical practice, including across across community, primary, secondary and community care. 
  
  
• This plan will:
  
  • Develop clear actions for adoption of pharmacogenomics within routine clinical practice.
  • Establish networks and governance structures 
    
    • Provide a roadmap to build infrastructure, including: 
    • Digital technology. 
    • Research and innovation. 
    • Workforce development. 
    • Clinical pathways.